Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease

OBJECTIVE: Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)can occasionally lead to interstitial lung disease (ILD), and the appropriate treatment after recovery from ILD remains controversial. AC0010 is an investigational third-generation TKI used in China to s...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Wang, Hanping, Zhang, Li, Shi, Xiaohua, Zhang, Xiaotong, Si, Xiaoyan
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2019
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6628610/
https://ncbi.nlm.nih.gov/pubmed/31371992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S204689
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky